Legis Daily

To provide for quality assurance of COVID-19 reimbursements and reporting.

USA117th CongressHR-311| House 
| Updated: 3/5/2021
Bill Posey

Bill Posey

Republican Representative

Florida

Crime and Federal Government Surveillance Subcommittee, Health Subcommittee, Judiciary Committee, Energy and Commerce Committee

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
This bill (1) establishes documentation requirements for testing, treatment, and reporting related to COVID-19 (i.e., coronavirus disease 2019); and (2) makes it unlawful to knowingly report a false diagnosis of COVID-19. To receive a federal reimbursement for the cost of a COVID-19 diagnostic test or treatment, the request for reimbursement must document that the administered COVID-19 test has been approved, cleared, or authorized by the Food and Drug Administration. Further, the Centers for Disease Control and Prevention must exclude from its official COVID-19 case and death counts any person who tested positive and requested federal reimbursement without the required documentation. Additionally, any person who knowingly reports a false diagnosis of COVID-19 is subject to criminal fines and imprisonment for not more than 10 years.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline

Bill from Previous Congress

HR 116-7037
To provide for quality assurance of COVID-19 reimbursements and reporting.
Jan 13, 2021
Introduced in House
Jan 13, 2021
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Feb 2, 2021
Referred to the Subcommittee on Health.
Mar 5, 2021
Referred to the Subcommittee on Crime, Terrorism, and Homeland Security.
  • Bill from Previous Congress

    HR 116-7037
    To provide for quality assurance of COVID-19 reimbursements and reporting.


  • January 13, 2021
    Introduced in House


  • January 13, 2021
    Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.


  • February 2, 2021
    Referred to the Subcommittee on Health.


  • March 5, 2021
    Referred to the Subcommittee on Crime, Terrorism, and Homeland Security.

Health

Cardiovascular and respiratory healthDrug safety, medical device, and laboratory regulationEmergency medical services and trauma careFraud offenses and financial crimesHealth care costs and insuranceHealth care coverage and accessHealth information and medical recordsHealth programs administration and fundingInfectious and parasitic diseasesMedical tests and diagnostic methods

To provide for quality assurance of COVID-19 reimbursements and reporting.

USA117th CongressHR-311| House 
| Updated: 3/5/2021
This bill (1) establishes documentation requirements for testing, treatment, and reporting related to COVID-19 (i.e., coronavirus disease 2019); and (2) makes it unlawful to knowingly report a false diagnosis of COVID-19. To receive a federal reimbursement for the cost of a COVID-19 diagnostic test or treatment, the request for reimbursement must document that the administered COVID-19 test has been approved, cleared, or authorized by the Food and Drug Administration. Further, the Centers for Disease Control and Prevention must exclude from its official COVID-19 case and death counts any person who tested positive and requested federal reimbursement without the required documentation. Additionally, any person who knowingly reports a false diagnosis of COVID-19 is subject to criminal fines and imprisonment for not more than 10 years.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline

Bill from Previous Congress

HR 116-7037
To provide for quality assurance of COVID-19 reimbursements and reporting.
Jan 13, 2021
Introduced in House
Jan 13, 2021
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Feb 2, 2021
Referred to the Subcommittee on Health.
Mar 5, 2021
Referred to the Subcommittee on Crime, Terrorism, and Homeland Security.
  • Bill from Previous Congress

    HR 116-7037
    To provide for quality assurance of COVID-19 reimbursements and reporting.


  • January 13, 2021
    Introduced in House


  • January 13, 2021
    Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.


  • February 2, 2021
    Referred to the Subcommittee on Health.


  • March 5, 2021
    Referred to the Subcommittee on Crime, Terrorism, and Homeland Security.
Bill Posey

Bill Posey

Republican Representative

Florida

Crime and Federal Government Surveillance Subcommittee, Health Subcommittee, Judiciary Committee, Energy and Commerce Committee

Health

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Cardiovascular and respiratory healthDrug safety, medical device, and laboratory regulationEmergency medical services and trauma careFraud offenses and financial crimesHealth care costs and insuranceHealth care coverage and accessHealth information and medical recordsHealth programs administration and fundingInfectious and parasitic diseasesMedical tests and diagnostic methods